Brigatinib

Overview

Brigatinib, also known as AP-26113, is an orally active, potent and selective dual ALK/EGFR inhibitor. AP26113 is an orally bioavailable inhibitor of anaplastic lymphoma kinase (ALK; IC50 < 100 nM in Ba/F3 cells). AP26113 binds to and inhibits ALK kinase and ALK fusion proteins as well as EGFR and mutant forms. It blocks ALK activity and reduces growth in neuroblastoma cells, mouse xenograft, and Drosophila model systems harboring constitutively active ALK variants.

Application

Products > Drug Discovery > Inhibitor | Products > Drug Discovery > Inhibitor | Cancer | ALK

Product Information

• Catalog No.: B0084-470820
• CAS No.: 1197953-54-0
• Molecular Formula: C29H39ClN7O2P
• Molecular Weight: 584.10
• Purity: ≥98%

Source

Original product source